More on Mayo Clinic researcher + Belgium biotech
Here's more detail on the latest action in the Mayo Clinic and Cardio3 relationship.
Cardio3 is a Belgium biotech that is hot in the running in the race to develop a regenerative heart treatment.
Through Mayo Clinic, a Rochester scientist is working at the heart of a Belgium biotechnology firm working on the Holy Grail of cardiac treatments - repair a damaged heart with a patient's own stem cells.
As part of a 2007 license agreement, Mayo Clinic owns equity in Cardio3 and collaborates on continuing research. However, it does not have a direct financial investment in the company, says Kathy Anderson, a Mayo Clinic spokeswoman.
Cardio3's breakdown of its investors on its website shows Mayo Clinic controls 30 percent of the company's capitalization.
Cardio3 Biosciences, which uses a patients stem cells from their bone marrow to repair heart damage, is riding high with early positive results from its “first‐in‐man” six month clinical trial of its C-Cure treatment for congestive heart failure.
“The data so far from our trial is very encouraging," said Cardio3 CEO Dr. Christian Homsy. "We showed that C‐Cure is safe at three months."
That clinical trial in Europe is scheduled to conclude in September.